IBM's Chicago Quantum Launch Meets a Harder Test: Can Earnings Keep Outrunning Revenue?

IBM has given its quantum ambitions a physical address. The company unveiled its Quantum System Two in Chicago this week alongside the University of Chicago, the State of Illinois and the Illinois Quantum and Microelectronics Park. The machine is already running at the Hyde Park Labs site and relies on the Nighthawk processor.

For shareholders, the ceremony raises a familiar question in sharper form: how much credit should a technical milestone earn against the slower, less glamorous work of hitting financial targets? Evercore ISI is happy to answer with a number. The brokerage reiterated its "Outperform" rating and a $275 price target on IBM, with a bull-case valuation of $290 a share built by summing the individual parts of the business. Notably, that arithmetic assumes neither divestitures nor a breakup — the upside is meant to come from the current setup, not from financial engineering.

The earnings ratio carries more weight than any ribbon-cutting

What separates a durable re-rating from a headline is whether profit keeps growing faster than sales. On that measure IBM has something to show. Revenue rose 6% in currency-adjusted terms, while diluted operating earnings per share climbed 11%. That gap is the operational backbone of Evercore's thesis, and it will be judged on whether the pattern repeats in coming quarters.

The top line tells a similar story. IBM reported third-quarter 2026 revenue of $17.1 billion on October 21, up 5%, and raised its free cash flow outlook at the same time. Management now expects free cash flow to rise by more than $1 billion year over year, while keeping its guidance for currency-adjusted revenue growth at 4–5%.

Those two disclosures — a working quantum computer and a lifted cash flow forecast — sit at very different distances from an investor's bank account. The first describes what IBM's engineers have built; the second describes what the finance department expects to deliver. Tying them into a single bullish case requires the company to convert research prowess into commercial traction, and to do so without stumbling on the numbers it has already promised.

Should investors sell immediately? Or is it worth buying IBM?

Research partnerships widen the runway

The Chicago system is not IBM's only bet on the technology's future. IBM is working with AMD and the Quantum Science Center at Oak Ridge National Laboratory on a shared research platform that pairs IBM quantum machines with classical high-performance computing. The work targets error correction, decoding and system coordination, with a link planned to the Oak Ridge Leadership Computing Facility to broaden research into integrated quantum, AI and scientific computing.

The division of labor is straightforward: IBM supplies the quantum hardware, AMD contributes classical compute and software. Findings are meant to feed into Starling, IBM's fault-tolerant quantum computer slated for delivery by 2029. Should the collaboration produce measurable gains and keep development on schedule, it would give the bull case a second leg to stand on.

The scale of the remaining climb is visible in the published figures. IBM reports up to 70 logical qubits and 438 so-called hard operations — a research benchmark against which future progress can be measured concretely. The U.S. Department of Energy's Quantum Genesis Mission has set a target of 100 logical qubits and 100,000 hard operations by the end of 2028. On the operations count in particular, the distance is considerable. Metrics on latency, decoding performance and logical error rates for the new research platform have not yet been released.

Beyond the lab, quieter deals keep compounding

IBM has not been idle on the commercial side while the physicists work. On October 27 it announced new identity and control features for AI agents, including the use of HashiCorp Vault Agent Identity to govern agent identities under controlled management. A day later, IBM and the USTA extended their partnership by five years, keeping IBM as the official AI and cloud partner of the US Open through 2031.

Set beside Chicago, the two announcements sketch a fuller picture: IBM is building the guardrails for autonomous software on one hand, and deepening an existing customer relationship on the other. The bull case gains weight if offerings and partnerships like these end up carrying the financial results — economically useful technology rather than a valuation resting on research trophies alone.

Where the thesis could come unstuck

The bear argument starts with the mismatch in scope. A functioning quantum system is a technical milestone; a cash flow forecast is a financial promise. Anyone combining the two into one investment case is effectively assuming IBM executes on both fronts at once.

IBM at a turning point? This analysis reveals what investors need to know now.

If delivery against the raised cash flow outlook comes under pressure, the financial floor beneath the thesis weakens. And because investors may already be pricing in substantial future value from quantum activities, the shares could prove more sensitive to disappointment than the fundamentals alone would suggest. That risk matters most for a position leaning heavily on long-term technological optionality.

The confirmed revenue target also frames expectations. A more generous valuation driven by Chicago alone would rest more heavily on distant assumptions; one supported by repeatable earnings growth would not. The negative scenario is a double miss — technical progress arriving more slowly while operating profit growth fades — which would sap both pillars of the positive case at once.

The near-term calendar belongs to the dividend

Until the numbers diverge from guidance, Chicago can be filed as an additional long-term opportunity. The next fixed date for shareholders comes first: IBM has set November 10 as the record date for its declared quarterly dividend of $1.69 per share, payable December 10. It is a scheduled event, not a verdict on strategy.

The real scorecard lies further out. Performance data on error correction would be a potential catalyst, though no publication date has been given. After that, the Quantum Genesis Mission target at the end of 2028 and Starling's planned delivery in 2029 mark the long-range checkpoints. In between, the quarterly earnings reports will decide whether Evercore's $275 target — and the more optimistic $290 — are earned or merely hoped for. Chicago strengthens the technological half of that ledger. The financial half still has to be delivered.

Ad

IBM Stock: New Analysis - 7 November

Fresh IBM information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated IBM analysis...